Practical Problems with Clinical Guidelines for Breast Cancer Prevention Based on Remaining Lifetime Risk

Journal of the National Cancer Institute

Volumn 107, Issue 7, 2015, Pages

  Quante, Anne S ^a,b,c   Whittemore, Alice S ^d   Shriver, Tom ^a   Hopper, John L ^e,f   Strauch, Konstantin ^b,c   Terry, Mary Beth ^a,g  

^a Mailman School of Public Health   (United States)

^b UNIVERSITY OF MUNICH   (Germany)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f Seoul National University   (South Korea)

^g New York Presbyterian Morgan Stanley Children's Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; FEMALE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; AGED; AREA UNDER THE CURVE; BREAST NEOPLASMS; COMPARATIVE STUDY; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; HETEROZYGOTE; INCIDENCE; KAPLAN MEIER METHOD; LIFE EXPECTANCY; MIDDLE AGED; MUTATION; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; RISK; RISK FACTOR; SENSITIVITY AND SPECIFICITY; STANDARDS; STATISTICAL MODEL; UNITED STATES; VERY ELDERLY;

BRCA1 PROTEIN; BRCA1 PROTEIN, HUMAN; BRCA2 PROTEIN; BRCA2 PROTEIN, HUMAN;

ADULT; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HETEROZYGOTE; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; LIFE EXPECTANCY; MIDDLE AGED; MODELS, STATISTICAL; MUTATION; ODDS RATIO; PRACTICE GUIDELINES AS TOPIC; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; ROC CURVE; SENSITIVITY AND SPECIFICITY; UNITED STATES;

EID: 84931010406     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djv124     Document Type: Article

References (25)

1. Bevers TB, Anderson BO, Bonaccio E, et al. NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis. J Natl Compr Canc Netw. 2009;7(10):1060-1096.
2. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989;81(24):1879-1886.
3. Gail MH, Costantino JP, Pee D, et al. Projecting individualized absolute invasive breast cancer risk in African American women. J Natl Cancer Inst. 2007;99(23):1782-1792.
4. Matsuno RK, Costantino JP, Ziegler RG, et al. Projecting individualized absolute invasive breast cancer risk in Asian and Pacific Islander American women. J Natl Cancer Inst. 2011;103(12):951-961.
5. Meads C, Ahmed I, Riley RD. A systematic review of breast cancer incidence risk prediction models with meta-analysis of their performance. Breast Cancer Res Treat. 2012;132(2):365-377.
6. Quante AS, Whittemore AS, Shriver T, et al. Breast cancer risk assessment across the risk continuum: genetic and nongenetic risk factors contributing to differential model performance. Breast Cancer Res. 2012;14(6):R144.
7. Claus EB, Risch N, Thompson WD. Autosomal dominant inheritance of earlyonset breast cancer. Implications for risk prediction. Cancer. 1994;73(3):643-651.
8. Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med. 2004;23(7):1111-1130.
9. Parmigiani G, Berry D, Aguilar O. Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet. 1998;62(1):145-158.
10. Antoniou AC, Cunningham AP, Peto J, et al. The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer. 2008;98(8):1457-1466.
11. Antoniou AC, Pharoah PD, McMullan G, et al. A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes. Br J Cancer. 2002;86(1):76-83.
12. Antoniou AC, Pharoah PP, Smith P, et al. The BOADICEA model of genetic susceptibility to breast and ovarian cancer. Br J Cancer. 2004;91(8):1580- 1590.
13. Whittemore AS. Evaluating health risk models. Stat Med. 2010;29(23):2438- 2452.
14. Anothaisintawee T, Teerawattananon Y, Wiratkapun C, et al. Risk prediction models of breast cancer: A systematic review of model performances. Breast Cancer Res Treat. 2012;133(1):1-10.
15. Amir E, Evans DG, Shenton A, et al. Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme. J Med Genet. 2003;40(11):807-814.
16. Laitman Y, Simeonov M, Keinan-Boker L, et al. Breast cancer risk prediction accuracy in Jewish Israeli high-risk women using the BOADICEA and IBIS risk models. Genet Res (Camb). 2013;95(6):174-177.
17. MacInnis RJ, Bickerstaffe A, Apicella C, et al. Prospective validation of the breast cancer risk prediction model BOADICEA and a batch-mode version BOADICEACentre. Br J Cancer. 2013;109(5):1296-1301.
18. Stahlbom AK, Johansson H, Liljegren A, et al. Evaluation of the BOADICEA risk assessment model in women with a family history of breast cancer. Fam Cancer. 2012;11(1):33-40.
19. John EM, Hopper JL, Beck JC, et al. The Breast Cancer Family Registry: An infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer. Breast Cancer Res. 2004;6(4):R375-R389.
20. Gong G, Quante AS, Terry MB, et al. Assessing the goodness of fit of personal risk models. Stat Med. 2014;33(18):3179-3190.
21. Whittemore AS, Halpern J. Two-stage sampling designs for external validation of personal risk models. Stat Methods Med Res. 2013; In press.
22. Heagerty PJ, Zeger SL. Multivariate continuation ratio models: connections and caveats. Biometrics. 2000;56(3):719-732.
23. Harrell FE, Jr., Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15(4):361-387.
24. Uno H, Cai T, Pencina MJ, et al. On the C-statistics for evaluating overall adequacy of risk prediction procedures with censored survival data. Stat Med. 2011;30(10):1105-1117.
25. Pepe MS, Longton G. Standardizing diagnostic markers to evaluate and compare their performance. Epidemiology. 2005;16(5):598-603